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Summary 
 
            Reduced kidney mass by uninephrectomy may result in multiple metabolic 
derangements, including insulin resistance (IR). In this regard, using the ‘gold standard’ 
hyperinsulinaemic-euglycaemic clamp technique, DeFronzo et al. found evidence of 
reduced insulin responsiveness in peripheral tissues of chronic kidney disease (CKD) 
patients, most likely in skeletal muscle tissues. However, the underlying mechanisms still 
remain unclear. The principal goal of the present project was to determine the impact of 
reduced kidney mass on glucose metabolism in lean and obese mice. To this end, male 
C57BL6/J mice underwent uninephrectomy (UniNx) or sham operation at 7 weeks of age. 
After surgery, animals were fed either chow (standard) or high fat diet (HFD). Glucose 
homeostasis was assessed 2, 8 and 20 weeks after surgery. No significant differences were 
observed in glucose tolerance between sham-operated and UniNx mice. However, skeletal 
muscle insulin resistance as assessed by hyperinsulinaemic-euglycaemic clamp was 
significantly deteriorated in HFD-fed UniNx mice, whereas insulin-stimulated glucose 
uptake into isolated skeletal muscle was similar between HFD-fed sham-operated and 
UniNx mice. Importantly, capillary density was significantly reduced in skeletal muscle of 
HFD-fed UniNx mice. In contrast, hepatic insulin sensitivity was improved and HFD-
induced adipose tissue inflammation was reduced in UniNx mice. Moreover, expression of 
hypoxia inducible factor 1-alpha (HIF1) was reduced in adipose tissue of HFD-fed UniNx 
mice. However, treatment with the angiotensin II type I receptor blocker i.e. telmisartan 
improved glucose tolerance and hepatic insulin sensitivity only in HFD-fed sham-operated 
mice but not HFD-fed UniNx mice. In conclusion, UniNx protects from obesity-induced 
adipose tissue inflammation and hepatic insulin resistance potentially via a reduction in 
HIF1expression. In contrast, UniNx reduces muscle capillary density, and thus 
deteriorates HFD-induced skeletal muscle glucose disposal in vivo. 
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Zusammenfassung 
 
            Eine reduzierte Nierenmasse infolge Uninephrektomie kann zu metabolischen 
Komplikationen wie zum Beispiel einer Insulinresistenz führen. Dementsprechend fanden 
DeFronzo und Kollegen in hyperinsulinämen-euglykämen Clamp Studien in Patienten mit 
chronischer Nierenkrankheit eine verminderte Insulinsensitivität in peripheren Geweben, 
wobei vermutlich vor allem der Skelettmuskel von einer Insulinresistenz betroffen war. Der 
dahinterliegende Mechanismus ist jedoch nicht vollumfänglich bekannt. Ziel dieses 
Projektes war es, den Einfluss einer reduzierten Nierenmasse auf den Zuckerstoffwechsel 
in schlanken und übergewichtigen Mäusen zu untersuchen. Dazu wurden männliche 
C57BL6/J Mäuse im Alter von 7 Wochen einer Uninephrektomie (UniNx) oder einer 
Scheinoperation unterzogen. Nach der Operation erhielten die Mäuse entweder eine 
Standardnahrung oder eine fettangereicherte Diät und der Zuckerstoffwechsel wurde 2, 8 
und 20 Wochen postoperativ untersucht. Dabei ergab sich kein Unterschied in der 
Glukosetoleranz zwischen scheinoperierten und uninephrektomierten Mäusen. Hingegen 
fand sich während hyperinsulinämen-euglykämen Clamp Studien in übergewichtigen 
Mäusen eine signifikant verschlechterte Insulinsensitivität in der Skelettmuskulatur in 
UniNx Mäusen, während die insulinstimulierte Glukoseaufnahme in die isolierte 
Skelettmuskulatur nicht beeinträchtigt war. Interessanterweise war die Kapillardichte in 
Skelettmuskeln von übergewichtigen UniNx Mäusen signifikant reduziert. Im Gegensatz 
zur Insulinsensitivität im Skelettmuskel fand sich eine verbesserte Leberinsulinsensitivität 
sowie eine reduzierte Entzündung im Fettgewebe in UniNx Mäusen. Ebenfalls war die 
Expression von HIF1 tiefer im Fettgewebe uninephrektomierter Mäuse. Eine Behandlung 
der Mäuse mit dem Angiotensin II Typ I Rezeptor Blocker Telmisartan verbesserte die 
Glukosetoleranz und die Leberinsulinsensitivität nur in übergewichtigen scheinoperierten, 
nicht aber in UniNx Mäusen. Zusammenfassend schützt eine Uninephrektomie von einer 
übergewichts-bedingten Entzündung des Fettgewebes sowie einer Leberinsulinresistenz, 
was vermutlich die Folge einer reduzierten Expression von HIF1ist. Im Gegensatz dazu
Zusammenfassung 
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 vermindert die Entfernung einer Niere die Kapillardichte im Skelettmuskel, was zu einer 
verschlechterten Glukoseaufnahme in vivo führt.
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1   Introduction 
 
1.1   Obesity 
1.1.1 Prevalence of obesity 
            Overweight, defined as a body mass index (BMI, defined as the individual’s body 
mass divided by the square of height) [1] equal to or more than 25 kg/m2, and obesity, 
defined as BMI greater than 30 kg/m2, are characterized by excessive fat accumulation 
resulting from an imbalance between energy intake and energy expenditure. Worldwide, it 
is estimated that there are more than 300 million obese adults [1]. According to the recent 
epidemiological reports, the prevalence of obesity is increasing in most societies, even 
among young adults and children [2, 3]. Furthermore, there is evidence that obesity is a 
major risk factor for the development of various diseases, the most devastating of which 
may be type 2 diabetes mellitus (T2DM) [4]. Concurrent with the rising prevalence of 
obesity is an epidemic of chronic kidney disease with an estimated 11% of the United 
States population currently affected [5]. It is estimated that 60% of all end stage renal 
disease (ESRD) patients who receive a kidney transplant are either overweight or obese at 
the time of transplantation [6]. Data from studies in the United States have suggested that, 
unabated, increasing demand for live-donor kidneys has encouraged the use of obese 
donors [7]. Obesity is affected by a complex interaction. Although the growing obesity 
epidemic reflects profound changes in diet and physical activity (sedentary life-style) over 
recent decades, genetic factors are important in determining individual’s susceptibility to 
weight gain and adverse health consequences of obesity [1]. Because of the increased 
health risks associated with obesity, the obesity epidemic places a large financial burden on 
the economy. It has therefore emerged as one of the most pressing global issues that we 
will face during the next several decades in the modern society. 
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1.1.2 Inflammation 
            In obesity, adipose tissue expansion is associated with local infiltration of different 
types of inflammatory cells, especially macrophages [8]. These macrophages are 
predominantly M1 polarized (CD11c+) and are characterized by increased release of 
proinflammatory cytokines, such as tumour necrosis factor (TNF)-, interleukin (IL)-6, 
and IL-1 among others [9, 10]. In contrast, adipose tissue of lean mice contains mainly 
alternatively activated, anti-inflammatory M2 macrophages [11]. The overproduction of 
proinflammatory cytokines contributes to the induction of insulin resistance (defined as the 
diminished ability of cells to respond to insulin, i.e. resulting in reduced glucose uptake 
into muscle and adipose tissue and decreased suppression of hepatic glucose output) both 
locally and systemically, i.e. in skeletal muscle and liver [12]. For instance, 
proinflammatory cytokines such as IL-6 reduce insulin-stimulated glucose uptake into 
adipocytes and skeletal muscle through its ability to inhibit tyrosine phosphorylation of 
IRS-1 [13, 14]. TNF- affects the stability of lipid droplets in adipocytes by decreasing 
perilipin expression [15]. In addition, TNF- was described to induce excess adipose 
lipolysis, which could drive fatty acid re-esterification and ectopic lipid accumulation, 
promoting impaired insulin signal transduction [16]. 
            Adipose tissue hypoxia may contribute to adipose tissue inflammation and develops 
as a consequence of limited vascular supply of expanding adipose tissue [17]. Hypoxia 
results in increased expression of hypoxia inducible factor 1-alpha (HIF1α) [18]. 
Importantly, selective inhibition of HIF1 was previously reported to reduce adipose tissue 
inflammation in obese mice [19]. Conversely, overexpression of HIF1 induced adipose 
tissue inflammation [20]. 
            Expression of pro-inflammatory cytokines may differ between fat depots. 
Especially, intra-abdominal fat depots (e.g. omental and mesenteric white adipose tissue) 
show a higher degree of cytokine expression [21, 22]. The increased release of pro-
inflammatory cytokines (and free fatty acids) from these depots directly drain into the 
portal vein which contributes to the development of hepatic insulin resistance and steatosis 
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[23]. In conclusion, adipose tissue inflammation is a hallmark of obesity and plays a role in 
the development of obesity-associated metabolic dys-regulation such as insulin resistance. 
 
1.1.3 Ectopic lipid accumulation 
In healthy subjects, white adipose tissue (WAT) is able to expand to store any 
surplus of calories as triglycerides. In obesity, however, the storage capacity of WAT may 
be limited [24]. Especially, expandability of subcutaneous adipose tissue is constricted 
resulting in increased lipid accumulation in intra-abdominal fat depots as well as in liver, 
skeletal muscle and heart [25, 26]. This ectopic fat deposition including intramyocellular 
triglyceride accumulation and production of toxic lipid metabolites may exert deleterious 
effects, such as impaired insulin signalling, in different tissues [27, 28]. Interestingly, 
ectopic lipid accumulation is also a characteristic feature of lipodystrophy, a disorder 
characterized by selective loss of body fat [29]. Consequently, adipose tissues cannot 
sufficiently buffer postprandial influx of fatty acids, resulting in increased fat storage in 
liver, skeletal muscle and other peripheral tissues and subsequently cause impairment of 
insulin signalling [25]. Importantly to the present thesis, studies in rodents suggest that 
reduced kidney mass due to uninephretomy may result in a state of acquired lipodystrophy 
leading to ectopic lipid deposition. 
 
1.1.4 Renin-angiotensin-system activation 
The renin-angiotensin-system (RAS) regulates blood pressure and water (fluid) 
balance [30, 31]. Moreover, there is growing evidence that activation of the RAS may play 
a role in obesity-associated insulin resistance [32]. Over the last decades, components of 
the RAS such as renin, angiotensinogen (AGT), angiotensin II (ATII) were thought to be 
exclusively produced by liver, kidney, and vasculature. However, current studies have 
prevailed that local RAS exists in numerous organs such as pancreas, heart, brain, and 
white adipose tissue (WAT) [33, 34]. Particularly, WAT synthesizes and secretes the major 
components of the RAS [35]. In obesity, the adipose RAS is activated. Several lines of 
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evidence have shown that adipose RAS overactivation may induce insulin resistance via 
increasing adipose tissue inflammation [32, 36]. Moreover, recent studies have suggested 
that inactivation of the RAS in animal models improves insulin sensitivity and protects 
from diet-induced obesity and insulin resistance [37-39]. In particular, telmisartan, which is 
an angiotensin II type 1 receptor blocker, was previously reported to improve obesity-
induced adipose tissue inflammation [40, 41]. These findings highlight the potential role 
for activation of the adipose RAS in the development of obesity-associated insulin 
resistance. Reduced renal function e.g. in the context of renal inflammation and reduced 
glomerular infiltration leads to increased activation of the RAS [42]. Moreover, it has been 
reported that chronic renal impairment was associated with fat redistribution and increased 
triacyglycerol levels and, thus, may contribute to the development of insulin resistance [43, 
44]. These findings therefore support the notion that chronic renal impairment may lead to 
adipose tissue dysfunction and insulin resistance via activation of the RAS. 
 
1.2   Insulin resistance  
1.2.1 Definition of insulin resistance 
Insulin resistance is a prerequisite for the development of T2DM and may be partly 
responsible for the increased risk of CKD [45, 46]. Clinically, insulin resistance can be 
broadly defined as a blunt biological response to normal levels of circulating insulin, 
resulting in compensatory hyperinsulinaemia [47]. Insulin resistance can be determined by 
the homeostatic model assessment HOMA–IR (calculated from fasting plasma glucose and 
fasting plasma insulin levels) or more sophisticatedly by hyperinsulinaemic-euglycaemic 
clamp studies (gold standard for the assessment of insulin resistance) [48, 49].  
            Insulin’s action in various tissues is complex and it regulates many biological 
processes. For instance, insulin increases glucose uptake in skeletal muscle and adipose 
tissue. In the liver, it suppresses hepatic glucose production [50, 51]. Additionally, it also 
stimulates lipogenesis and triglyceride secretion, regulates many other processes including 
bile acid metabolism, growth and differentiation [52-54]. Clinical definition of insulin 
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resistance implies that all of these processes become resistant, though this is unlikely to be 
true. Indeed, some pathway remains sensitive to insulin, while other pathways become 
resistant, particularly glucose uptake into skeletal muscle and inhibition of hepatic glucose 
production [55-57]. Therefore, insulin resistance may appear in one of the target organs 
even in the absence of systemic impaired glucose homeostasis. 
 
1.2.2 Insulin signalling pathway 
Insulin is synthesized and secreted by pancreatic -cells dependent on blood 
glucose concentration. Upon binding of insulin, the insulin receptor is auto-phosphorylated 
leading to activation of its endogenous tyrosine kinase and subsequently phosphorylating 
tyrosine residues on insulin receptor substrate (IRS) [58]. Two major signalling pathways 
are activated in response to insulin: the phosphoinositide 3-kinase (PI3K) and the mitogen-
activated protein (MAP) kinase pathway. Tyrosine phosphorylation of insulin receptor 
substrates (IRS) activates phosphatidylinositide-3-kinase (PI3K), this providing a docking 
site for the p85 regulatory subunit and releasing the p110 catalytic subunit. PI3K triggers 
activation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) kinase and Akt 
kinase [50, 59]. The PI3K-Akt pathway is responsible for many of the downstream 
metabolic effects of insulin [60]. In skeletal muscle and adipose tissue, Akt kinase 
stimulates translocation of insulin-sensitive glucose transporter (GLUT4) to the plasma 
membrane and facilitates the glucose uptake [61]. In vascular endothelial cells, Akt kinase 
phosphorylates and activates endothelial nitric oxide synthase (eNOS) [62]. In parallel, 
tyrosine phosphorylation of the Shc protein activates the GTP exchange factor Sos [63]. 
This may result in inactivation of the MAP kinase pathway, involving Ras, MAP kinase and 
extracellular regulated kinase (ERK). The MAP kinase pathway mediates endothelin-1 
(ET-1) production, leading to vasoconstriction, growth and mitogenesis effects on vascular 
smooth muscle cells, and among others (Figure 1) [64]. Insulin resistance may occur as a 
result of interference with the insulin signalling cascade at any level [65]. 
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Figure 1. Signal transduction in insulin action. The insulin receptor is a tyrosine kinase that undergoes 
autophosphorylation and catalyses the phosphorylation of cellular proteins such as members of the IRS 
family, Shc. Upon tyrosine phosphorylation, these proteins interact with signalling molecules, resulting in a 
diverse series of signalling pathways, including activation of PI3K, ras and the MAP kinase cascade. These 
pathways act in a concerted fashion to coordinate the regulation of glucose, lipid and protein metabolism 
(modified from Taniguchi et al. 2006 [50], the illustration was created in part with Servier Medical Art, 
www.servier.com). 
 
1.2.3 Metabolic effects of insulin resistance in adipose tissue and liver 
Accumulation of triacyglycerol in adipose tissue, as in obesity, is associated with 
insulin resistance [66]. In contrast, as outlined above, deficiency of adipose tissue as in 
lipodystrophy is also associated with insulin resistance [67, 68]. As a result, there is an 
increased release of free fatty acids (and cytokines) and subsequently ectopic fat 
deposition. All these changes may impair insulin signalling in different tissues. 
Interestingly, both obesity and lipodystrophy are related to CKD [69]. Experimentally, 
reduced kidney mass as established by uninephrectomy in rats results in lipodystrophy and 
is accompanied by low-grade inflammation [44, 70].   
            Ectopic lipid accumulation in the liver is associated with hepatic steatosis as well as 
hepatic insulin resistance [71, 72]. Both conditions are also associated with chronic low-
Introduction 
7 
 
grade inflammation in WAT [73, 74]. The portal theory claims that an excess flow of FFAs 
and pro-inflammatory cytokines arising from insulin-resistant visceral adipose tissue in 
obesity are rapidly translocated to the liver via portal circulation, where they reassembled 
into triglycerides, promoting the development of hepatic steatosis and induce insulin 
resistance [23]. 
 
1.2.4 Defects of insulin resistance and microcirculation in skeletal muscle 
Skeletal muscle plays a major role in glucose metabolism, accounting for 80% of 
whole-body insulin stimulated glucose disposal [75]. It has been suggested that skeletal 
muscle lipid oversupply is associated with insulin resistance [76]. Skeletal muscle insulin 
resistance is the result of reduced IRS-1 activation of PI3K and, consequently, diminished 
GLUT4 translocation to the membrane surface [77]. In addition to facilitating the transport 
of glucose into muscle cells, insulin increases microvascular perfusion of the muscle and 
that accounts for approximately half of the insulin-mediated glucose uptake [78-80]. The 
increase in insulin-mediated microvascular recruitment is diminished in states of insulin 
resistance and, thus, reduced muscle tissue perfusion contributes to insulin resistance [81, 
82]. Accordingly, insulin resistant subjects exhibit capillary rarefaction [79, 83, 84]. 
Underlying mechanisms leading to diminished insulin mediated blood flow remain unclear. 
 
1.3   Type 2 diabetes mellitus 
1.3.1 The development of type 2 diabetes mellitus 
The incidence and prevalence of diabetes mellitus is increasing worldwide over the 
last decades [85]. Epidemiological data show that over three hundred million people were 
diagnosed with type 2 diabetes mellitus (T2DM) in 2010 and the prevalence will further 
rise at an alarming rate [86]. The nature of the inherited defect of diabetes is still unknown, 
but acquired metabolic abnormalities are closely linked to several factors, in particular 
obesity. Indeed, obesity is believed to account for 80% of the risk of developing T2DM [87, 
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88]. Obesity initially leads to the development of insulin resistance in adipose and other 
tissues. Consequently, insulin resistance is compensated by increased insulin secretion. 
However, the pancreatic beta cells eventually fail to produce sufficient amount of insulin to 
overcome insulin resistance, leading to hyperglycaemia and ultimately T2DM [89]. 
Chronic inflammation especially in adipose tissue appears to play a major role in disease 
development and progression [66]. As previously mentioned, released proinflammatory 
cytokines may induce insulin resistance and contribute to beta cell dysfunction. 
Accordingly, such inflammatory mediators appear to be markers to predict impaired 
glucose tolerance [90-92]. 
 
1.3.2 Diabetic nephropathy 
            T2DM is associated with increased morbidity and mortality due to complications 
occurring as a consequence of chronic hyperglycaemia and/or chronic hyperinsulinaemia 
[93]. Especially, eyes, kidneys, the nervous system, and peripheral arteries are often 
affected [94, 95]. Diabetic nephropathy is characterized by increasing microalbuminuria, 
decreasing glomerular filtration rate, hypertension and other diabetic-associated 
complications [96]. It is a progressive disease and may lead to end stage renal disease 
(ESRD) with the need for dialysis or kidney transplantation [97]. T2DM is the most 
common cause for acquired ESRD in Western society and, thus, the rapidly rising trend of 
T2DM prevalence is of major concern [98, 99]. 
Undoubtedly, T2DM is causing chronic kidney dysfunction. However, there is 
evidence that the opposite may be also true, i.e. that reduced kidney function/mass may 
facilitate the development of the metabolic syndrome as suggested for kidney donors [100]. 
Moreover, Ibrahim et al. reported on 154 living kidney donors developing T2DM after 
kidney donation [101]. In addition, uninephrectomy in rats was reported to impair glucose 
tolerance [43, 44]. However, the underlying mechanisms are poorly understood. 
Furthermore, such data are rather scarce and further investigation is needed. 
 
 
Introduction 
9 
 
1.4   Chronic kidney disease  
1.4.1 The risk of chronic kidney disease  
The kidneys play an important role in the maintenance of whole body homeostasis. 
Notably, the kidneys contribute to the regulation of fluid, electrolyte and acid-base balance, 
to the excretion of metabolic waste, and, most relevant to the discussion of this project, to 
glucose metabolism [102, 103]. The kidneys reabsorb around 180 g of glucose per day, 
thereby assisting to maintain normal fasting plasma glucose levels at ~5-6 mmol/l which 
ensures that sufficient energy is available especially for the brain during fasting periods 
[104]. However, when plasma glucose concentration exceeds 12 mmol/l which is the 
maximal reabsortive capacity of the two kidneys, glycosuria will occur [105]. CKD 
represents a progressive and irreversible decline in kidney function and is characterized by 
a glomerular filtration rate (GFR) of less than 60 ml/min per 1.73 m2 for more than three 
months [106]. Decreased GFR is associated with obesity, diabetes, hypertension, and 
dyslipidaemia [107-109].  
            There is increasing evidence that obese patients are more susceptible to the 
development of CKD [110]. Studies demonstrate that subjects with severe obesity develop 
proteinuria with glomerular enlargement, mesangial expansion, podocyte hypertrophy, and 
glomerular sclerosis [111-113]. Virtually, all chronic kidney diseases are usually 
progressive and may lead to renal failure [106, 114]. Renal failure is a loss of renal function 
characterized by uraemia and retention of nitrogenous waste in the blood [106]. Around 
30%aof all diabetics develop evidence of nephropathy which may lead to ESRD and the 
latter is the leading cause for kidney transplantation in most countries [115]. It has resulted 
in a markedly increased demand for live kidney donors [97]. Conversely, it remains unclear 
whether CKD per se can induce T2DM and other components of the metabolic syndrome. 
However, there is evidence for mild fasting hyperglycaemia and abnormal glucose 
tolerance in nondiabetic patients with ESRD [116, 117]. In addition, live kidney donors 
may have impaired glucose homeostasis [101, 118]. Yet, available evidence is largely 
unrecognized.  
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1.4.2 Animal model of uninephrectomy and diet-induced obesity 
            Reduced kidney mass can experimentally be induced in rodents by uninephrectomy 
[119, 120]. This model closely resembles progressive renal disease in human and it shows a 
high degree of reproducibility [121]. Thus, uninephrectomy may be a preferred model of 
mimicking the clinical situation of kidney donation [122]. However, some rodent studies 
suggest that contralateral uninephrectomy and the resulting mild decreased kidney function 
was not enough to cause progression, and that, accelerants were essential [123, 124]. In the 
present study, diet-induced obesity was used as an accelerant of disease progression in 
mouse uninephrectomy model. It was previously reported that uninephrectomy in rats was 
associated with elevated expression of angiotensin type 1 receptor and insulin resistance 
[43]. In addition, uninephrectomy leads to adipose tissue redistribution with increased 
visceral adipose tissue mass known to be associated with the development of (hepatic) 
insulin resistance [44]. Thus, uninephrectomy may be a good model to study the impact of 
reduced kidney mass on glucose homeostasis and the development of insulin resistance. 
 
1.4.3 Crosstalk of kidney disease with adipose tissue, liver, and skeletal 
muscle 
Recent studies suggested that obesity, which is associated with adipose tissue 
dysfunction, contributes to the observed increase in the incidence of CKD [125, 126]. 
Accumulating data demonstrated that renal lipid accumulation and lipotoxicity in diet-
induced obese mice may lead to kidney dysfunction [127, 128]. Conversely, experimental 
studies showed that CKD induced by uninephrectomy is associated with adipose tissue 
dysfunction, resulting in ectopic lipid stores in multiple organs [70]. In a model of 
uninephrectomised rats, Zhao et al. reported that uninephrectomy-associated lipodystrophy 
may lead to ectopic lipid redistribution in liver, skeletal muscle, kidney and many other 
tissues [44]. Additionally, the uninephrectomised rats developed glucose intolerance and 
hyperinsulinaemia [43]. Thus, these studies provide evidence for a crosstalk between the 
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injured kidney and distant organs, particularly adipose tissue, liver, and skeletal muscle 
(Figure 2). Previous reports have revealed that abnormalities in lipid and glucose 
metabolism in the kidney contribute to the development of dysfunction in other organs such 
as adipose tissue. It was hypothesized that such adipose tissue dysfunction then resulted in 
ectopic lipid redistribution [70]. In addition, ongoing crosstalk between kidney and adipose 
tissue may impact on the secretion pattern of adipocytokines and RAS components 
contributing to the development of systemic insulin resistance and inflammation [39, 129]. 
Moreover, the increased production and release of pro-inflammatory cytokines from 
(visceral) adipose tissue promote the development of hepatic insulin resistance and 
steatosis as suggested by the portal theory [23].  
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Figure 2  Dysfunctional crosstalk between kidney, adipose tissue, liver, and skeletal muscle. Chronic 
kidney disease induces adipose tissue dysfunction. Adipose tissue dysfunction with limited ability to store 
excess energy results in lipid deposition at nonadipose sites such as liver, skeletal muscle and kidney. 
Intracellular lipid accumulation might impair insulin signalling, leading to insulin resistance and 
dyslipidaemia, and eventually promote multiple organ injuries.  
 
            On the other hand, CKD as well as obesity may promote ectopic lipid accumulation 
resulting non-alcoholic fatty liver disease (NAFLD) [70, 130, 131]. NAFLD can exacerbate 
hepatic insulin resistance and subsequently further increase in whole-body insulin 
resistance [132]. Besides promoting ectopic lipid accumulation, CKD is associated with 
increased activation of the RAS, which was demonstrated to contribute to the development 
of hepatic fibrogenesis [133, 134]. Thus, CKD may propagate (obesity-associated) adipose 
tissue dysfunction as well as hepatic steatosis and insulin resistance.  
Recent experimental and clinical evidence demonstrated evidence for a cross-talk 
between skeletal muscle and kidney in the pathogenesis of obesity-related renal disease. In 
patients with CKD, muscle atrophy is common and studies of animal models of CKD 
indicate that kidney dysfunction is associated with muscle atrophy through activation of 
angiotensin II (Ang II) [44, 135, 136]. The catabolic effect of Ang II is mediated by 
impaired insulin /IGF-1 intracellular signalling leading to protein degradation in muscle 
[137, 138]. Such phenomenon may be responsible, at least in part, for the observed 
reduction of muscle mass, as RAS is frequently activated in the progression of renal disease 
[139-141]. In addition, animal models of CKD reported an association between ectopic 
lipid accumulation and insulin resistance [43, 70]. As outlined above, accumulation of 
intramyocellular lipids inhibits insulin signalling by activating PKC- resulting in skeletal 
muscle insulin resistance [142, 143]. Importantly, DeFronzo et al. demonstrated that 
peripheral insulin-mediated glucose uptake was decreased in patients with ESRD [116]. 
However, cellular mechanisms linking CKD to skeletal muscle lipid accumulation and/or 
insulin resistance remain to be fully clarified.  
Thus, kidney function may not only deteriorate in the progression of obesity but 
kidney dysfunction may also negatively impact on adipose function and (consequently) to 
total-body insulin sensitivity.  
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1.5   Aim of the study 
Reduced kidney mass deteriorates insulin sensitivity. However, underlying 
mechanisms are poorly understood. In the present thesis, we hypothesize that reduced 
kidney mass impairs glucose metabolism and insulin sensitivity via activation of the RAS 
in adipocytes (Figure 3). 
 
 
Figure 3  Schematic illustration of possible mechanisms leading to adipose tissue dysfunction, and 
subsequently to insulin resistance in individuals with reduced kidney mass. Reduced kidney mass 
may impair or alter adipose tissue function through two different mechanisms: 1) it may induce chronic 
renal impairment; 2) activation of the RAS 
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2    Materials and methods 
2.1    Animals 
            Male C57BL/6J (C57BL/6JOlaHsd) mice were purchased from Harlan Netherlands 
(Harlan, Horst, the Netherlands). All mice were housed in a specific pathogen-free 
environment on a 12-hours-light-dark cycle (light on from 7 pm to 7 am) and fed ad libitum 
with regular chow diet (ProvimiKliba, Kaiseraugst, Switzerland) or high fat diet (HFD) (58 
kcal% fat w/sucrose Surwit Diet, D12331, Research Diets). All protocols conformed to the 
Swiss animal protection laws and were approved by the Cantonal Veterinary Office in 
Zurich, Switzerland.  
 
2.2    Diets 
            Table I lists the ingredients of the chow diet and high fat diet.  
Table 1 Content of chow and high fat diet. 
Ingredients Chow diet High-fat diet 
Protein (kcal%) 31 16.4 
Carbohydrate (kcal%) 57 25.5 
Fat (kcal%) 12 58.0 
 
2.3    Surgical procedure 
            Male C57BL/6J mice underwent uninephrectomy or sham operation at 7 weeks of 
age. Mice were anaesthetized with isoflurane (Abbott, Baar, Switzerland). Eye ointment 
(Vitamin A “Blanche”, Bausch & Lomb Swiss AG) was applied to both eyes. Mice were 
placed on a warming-pad and kept under an infrared heating lamp to stabilize body 
temperature during the whole surgical procedure. Left nephrectomy was performed through 
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a 1.0 cm incision on left dorsolateral paralumbar region as follows (Figure 4). After skin 
incision, abdominal muscles were incised to expose retroperitoneal region. Left kidney was 
secured with a clamp (FRANCIS chalazion forceps, D-8425) and fat attached to kidney 
was removed. Special care was taken to prevent damage to the adrenal gland. Renal blood 
vessels and ureter were ligated with sterile silk surgical sutures (DeknatelR Silk). 
Subsequently, left kidney was excised distal to ligatures. Abdominal muscles were sewn 
with reabsorbal thread (Vicryl* 5-0, ETHICON V303H) and opposite ends of incised skin 
was clipped together using sterile disposable skin staplers (3M PreciseTM REF. DS-25). 
Sham-operated control mice underwent identical surgical procedure except for kidney 
removal. Subcutaneous injection of buprenorphine (Essex, Luzern, Switzerland) every 6 
hours for 2 days was used for analgesia. The mice were monitored until they recovered 
from anaesthesia and returned to its home cage. 
 
                        
 
 
 
 
2.4    Maintenance of mice with telmisartan-treatment 
      After surgery, the HFD-fed mice were randomized to two groups. The mice were 
given either telmisartan (Boehringer Ingelheim International GmbH, MTA 1037) 
(~3mg/kg*day) in drinking water, or without any drug in drinking water for 20 weeks. The 
body weight of the animals was monitored once a week. To ensure the delivery of drug 
A 
Figure 4  Surgical procedure of uninephrectomy. Left uninephrectomy was performed at 7 weeks of 
age. A: The left dorsolateral paralumbar region was opened. The left adrenal gland (white arrow) and the 
left kidney (black arrow) were visualized. B: Left kidney was secured with a clamp and was then excised 
distal to the ligature.  
 
 
B 
Materials and methods 
16 
 
doses, the concentrations of the drugs in drinking water were adjusted weekly according to 
the body weight and water assumption.  
 
2.5    Intraperitoneal glucose and insulin tolerance tests  
            For intraperitoneal glucose tolerance test (ipGTT) mice were fasted overnight and 
for intraperitoneal insulin tolerance tests (ipITT) for 3 hours. Either glucose (2g/kg body 
weight) or human recombinant insulin (1.0 U/kg body weight) were injected 
intraperitoneally by a gavage needle (0.30mm (30G) x 8mm; BD Micro-Fine, Becton 
Dickinson, France) [144]. Blood glucose concentration was measured with a Glucometer 
(Contour Blutzuckermessgerät; Bayer HealthCare, Basel, Switzerland) with blood from 
tail-tip bleedings at different time points (i.e. 0, 15, 30, 45, 60, 90 and 120 minutes). Area 
under the curve (AUC) was calculated as changes from zero. 
 
2.6    Hyperinsulinaemic-euglycaemic clamp  
            After mice were anaesthetized (as described previously in surgical procedure), a 
catheter for intravenous infusion of solution during clamp was inserted into the jugular vein 
in each mouse. After recovery from the intravenous catheterization surgery, glucose clamp 
studies were performed in freely moving mice 20 weeks after uninephrectomy. Glucose 
infusion rate was calculated once glucose infusion reached a more or less constant rate with 
blood glucose levels at 5 mmol/l (80–90 min after the start of insulin infusion). Thereafter, 
blood glucose was kept constant at 5 mmol/l for 20 min and glucose infusion rate was 
calculated [145]. The glucose disposal rate was calculated by dividing the rate of [3-3H] 
glucose infusion by the plasma [3-3H]glucose specific activity [146]. Endogenous glucose 
production during the clamp was calculated by subtracting the glucose infusion rate from 
the glucose disposal rate [146, 147]. Insulin-stimulated glucose disposal rate was calculated 
by subtracting basal endogenous glucose production (equal to basal glucose disposal rate) 
from glucose disposal rate during the clamp [148]. In order to assess tissue specific glucose 
uptake, a bolus (10 μCi) of 2-[1-14C]deoxyglucose was administered via catheter at the end 
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of the steady state period. Blood was sampled 2, 15, 25 and 35 min after bolus delivery. 
Area under the curve of disappearing plasma 2-[1-14C]deoxyglucose was used together 
with tissue-concentration of phosphorylated 2-[1-14C]deoxyglucose to calculate glucose 
uptake [149]. 
 
2.7    Metabolic cage analysis 
            Eight metabolic cages in an open-circuit indirect calorimetric system were used 
(PhenoMaster, TSE Systems, Bad Homburg, Germany). Food and water intake, O2 
consumption, and CO2 production were determined for single housed mice during a 24-h 
period as follows [150]. After being adapted to single caging, mice were placed in cages 
closed with air-tight lids. Water bottles and food cups were placed on scales to measure 
water and food intake continuously. The measurements were saved on a computer in 20 
min intervals and were used to calculate cumulative food and water intake. Activity data 
were measured using an infrared light-beam. To measure energy expenditure (EE) and 
respiratory exchange ratio (RER), ambient air was pumped through the cage via a flow 
controller. Air entering and leaving each cage was monitored for its O2 and CO2 
concentration. The cages were connected to two analysers measuring O2/CO2 
concentration of each cage for a period of 2 min in 20 min intervals. EE and RER were 
calculated using the manufacturer's software based on the following equation: EE (kcal/h) 
= (3.941×VO2+1.106×VCO2)/1000; RER=VCO2/VO2. 
 
2.8    Determination of insulin, free fatty acid, angiotensin I,    
creatinine, uric acid and bile acid levels  
            Plasma was collected from the tail vein after 7 hours of fasting. Insulin was 
determined using an ELISA kit (Ultra Sensitive Rat Insulin ELISA; Crystal Chem, 
Downers Grove, IL, USA). Free fatty acid levels were measured using the ACS-ACOD-
MEHA method (Wako Chemicals GmbH, Neuss, Germany). Plasma angiotensin I levels 
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were determined by an ELISA kit (Cusabio Biotech CO Ltd, Wuhan, PR China). Serum 
creatinine levels were measured using DetectX® Low Sample Volume Serum Creatinine 
Kit (K0021-H1D, Arbor Assays, Ann Arbor, MI, USA), serum uric acid levels by 
QuantiChromTM Uric Acid Assay Kit (DIUA-250, BioAssay Systems, Hayward, CA, USA) 
and plasma bile acid levels using Mouse Total Bile Acids Assay Kit (80470, Crystal Chem 
Inc, Downers Grove, IL, USA). 
 
2.9    Total liver lipid extraction 
            Liver tissue (30 mg) was homogenized in PBS, and lipids were extracted in a 
chloroform/methanol (2:1) mixture. Total liver lipids were determined by a sulfo-phospho-
vanillin reaction as described by Knight et al. [151]. The liver lipid samples were heated at 
900C on heating block until dry and then cooled down on ice. Sulphuric acids were added 
to the samples and boiled at 900C in water bath for 10 min and cooled down on ice. 
Vanillin-reagent was added to the samples and incubated for 40 min at room temperature. 
Samples were transferred to a 96 well plate and detected by an Elisa-reader at 550 nm.  
 
2.10  Glucose incorporation into isolated soleus and EDL muscle  
            Mice were fasted for 4 hours prior to the analysis. Extensor digitorum longus (EDL) 
and soleus muscles were removed from anesthetized mice (Avertin, 99% 2,2,2-tribromo 
ethanol, and tertiary amyl alcohol at 15–17 μl/g body weight i.p.) and incubated for 30 min 
at 300C in vials containing preoxygenated (95% O2-5% CO2) Krebs-Henseleit buffer 
(KHB) containing 5 mM HEPES (prebuffer) and supplemented with 15 mM mannitol and 
5 mM glucose. Muscles were transferred to new vials containing fresh pre-gassed KHB, as 
described above, in the absence or presence 120nM of insulin (Actrapid; Novo Nordisk, 
Mainz, HE, Germany). Afterwards, muscles were transferred to new vials containing 
preoxygenized KHB supplemented with 20 mM mannitol and incubated for 10 min. 
Muscles were then transferred to new vials containing preoxygenized KHB supplemented 
with 1 mM [3H]2-deoxy-glucose (2.5 μCi/ml), and 19mM [14C]mannitol to account for 
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extracellular space, and incubated for 20 min. After the last incubation, muscles were 
washed in ice-cold KHB, dried externally on filter paper, and quickly frozen with 
aluminium tongs precooled in liquid nitrogen and stored at −80°C. Glucose transport rates 
were determined by scintillation counting of cleared protein lysates as described [152].  
 
2.11  Insulin signalling in skeletal muscle ex vivo  
            For assessing insulin-stimulated Akt phosphorylation in skeletal muscle, insulin 
(2U/kg) was injected intraperitoneally in mice fasted for 5 hours. Skeletal muscles 
(quadriceps) were harvested 15 minutes after insulin injection, snap frozen in liquid 
nitrogen and stored at -80°C until homogenization. Samples were further assessed by 
Western blotting. 
 
2.12  Histology 
            Epididymal fat tissues were fixed in 4% buffered formalin and embedded in 
paraffin. Sections were cut and stained with hematoxylin and eosin. After slides were air-
dried, 1-2 drops immu-Mount were added and then cover slip was applied. For each fat pad 
at least 100 adipocytes were analysed. Quadriceps femoris muscle was mounted in 
embedding medium (o.c.t. embedding matrix, CellPath Ltd., Newtown, UK), snap frozen in 
isopentane cooled to -160°C with liquid nitrogen, and subsequently stored at -80°C until 
use. Consecutive 12 µm sections were cut on a microtome at -25°C. Rat anti-mouse CD31 
endothelial cell antibody (BioLegend, San Diego, CA) was used as a marker for muscle 
capillaries, and capillary-to-fiber ratio was calculated by dividing the number of CD31-
positive cells by the number of muscle fibers. For all histochemical and 
immunohistochemical analyses NIH Image J software (National Institutes of Health, 
Bethesda, MD, USA) was used. 
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2.13  RNA extraction and quantitative rt-PCR 
            Total RNA was extracted with the RNAeasy Lipid Tissue Mini Kit (Qiagen). RNA 
was analysed with a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and 
concentration was determined with a nanodrop. RNA (0.75 g) was reverse transcribed 
with Superscript III Reverse Transcriptase (Invitrogen) using random hexamer primers 
(Invitrogen). TaqMan system (Applied Biosystems) was used for real-time PCR 
amplification. The amplification consisted of a 2 min period at 500C to activate the Uracil-
N-Glycosylase. Samples were heated to 950C followed by 40 cycles with denaturation at 
950C for 14 seconds and annealing/elongation at 600C for 1 minute. Relative gene 
expression was obtained after normalization to 18s RNA (Applied Biosystems), using the 
formula 2-ΔΔcp [153]. The following primers were used: TNF-α Mm00443258_m1, IL-6 
Mm00446190_m1, IL-1β Mm0043422/8_m1, CD11c Mm00498698_m1, ATGL 
Mm00503040_m1, perilipin Mm00558672_m1, HIF1α Mm00468869_m1, CD31 
Mm01242584_m1 (Applied Biosystems, Rotkreuz, Switzerland). 
 
2.14  Western blotting 
            Cells or tissues were lysed in ice-cold lysis buffer containing 150 mM NaCl, 50 
mM Tris-HCI (pH 7.5), 1 mM EGTA, 1% NP-40, 0.25% sodium deoyxcholate,  1 mM 
sodium vanadate, 1 mM NaF, 10 mM sodium -glycerolphosphate, 100 nM okadaic acid, 
0.2 mM PMSF and a 1:1000 dilution of protease inhibitor cocktail (Sigma-Aldrich). 
Protein concentration was determined using a BCA assay (Pierce, Rockford, IL, USA). 
Equivalent amounts of protein (20-50 g) were resolved by LDS-PAGE (4%-12% gel; 
NuPAGE, Invitrogen, Basel, Switzerland). Proteins were electro-transferred to a 
nitrocellulose membrane (0.2 m, BioRad, Reinach, Switzerland) and blocked for 1 hour in 
5% non-fat dry milk (BioRad) resolved in Tris-buffer saline, containing 1% Tween-20. 
Membranes were incubated overnight at 4o C on a rocking platform with respective primary 
antibodies. The following primary antibodies were used: anti-phospho-Akt (Ser473) (Cell 
Signalling, Danvers, MA, USA) and anti-actin (Millipore, Zug, Switzerland). 
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Subsequently, membranes were incubated with secondary antibody (HRP-conjugated; 
Santa Cruz Biotechnology and Alexis Biochemicals) for 1 hour at room temperature. 
Signals were generated after 5 minutes incubation with Lumi-Light chemoluminiscence 
(Roche). Membrane was exposed and signals were detected in an Image Analyser 
(FujiFilm) [153].  
 
2.15  Data analysis 
            Data are presented as mean +/- SEM and were analyzed by unpaired Student’s t test. 
P-values < 0.05 were considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
22 
 
3   Results 
3.1   General adaptations of UniNx and sham-operated mice to  
surgical intervention 
3.1.1 Similar body weight in sham-operated and UniNx mice 
            Dependent on the surgical intervention, mice were divided into two groups: sham-
operated or UniNx mice. Mice were then fed either a chow or high-fat diet (HFD) for up to 
20 weeks. Body weight was determined in weekly intervals. As expected, body weight gain 
of HFD-fed animals was significantly higher than that of chow-fed mice. Uninephrectomy 
had no significant influence on body weight neither in HFD-fed nor in chow-fed mice. 
However, there was a tendency towards decreased weight gain in UniNx mice as compared 
to sham-operated mice under both chow and HFD (Figure 5). 
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3.1.2 Increased epididymal fat pad weight in HFD-fed UniNx mice 
            After 20 weeks of surgery, remnant kidneys of both chow and HFD-fed UniNx 
mice were heavier compared to sham-operated mice. Liver weights of HFD-fed animals 
Figure 5  Body weights of uninephrectomised (UniNx) and sham-operated mice. Results are means and 
SEM of 7 to 17 animals per group. *p < 0.05 (Student’s t test).      Sham chow;      UniNx  chow;      sham 
HFD;     UniNx HFD. 
 
 
 
 
 
 
 
 
 
Results 
23 
 
were significantly heavier than those of chow-fed mice. However, no difference in liver 
weights were observed between sham-operated and UniNx mice (Figure 6A). In HFD-fed 
animals, epididymal fat pad weight was significantly higher in UniNx mice, whereas 
inguinal and mesenteric fat pad weights were similar in HFD-fed UniNx and sham-
operated mice. No differences in fat pad weights were observed in chow-fed mice (Figure 
6B). 
 
 
 
 
 
 
 
 
 
3.1.3 Similar food intake, locomotion and respiratory quotient in sham-
operated and UniNx mice 
            Food intake, locomotion, and fuel utilization (respiratory quotient, RQ) were 
determined in metabolic cages. As depicted in Figure 7, these parameters were similar 
between HFD-fed sham-operated and UniNx mice. 
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Figure 6  Organ weights were assessed 20 weeks after surgery. (A) Absolute weight of kidneys (r: right; l: 
left) and livers of HFD-fed sham-operated and UniNx mice are depicted. (B) Different fat pads were 
harvested and weighed. Results are means and SEM of 7 to 13 animals per group. **p < 0.01, ***p < 0.001 
(Student’s t test).      Sham chow;     UniNx chow;     sham HFD;     UniNx HFD. 
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3.1.4 Similar circulating blood metabolites in sham-operated and UniNx mice 
            Fasting blood glucose levels, as readout for hepatic glucose production, were 
similar in HFD-fed sham-operated and UniNx mice (Table 2). Interestingly, plasma insulin 
levels were significantly lower in chow-fed UniNx compared to sham-operated mice, 
whereas no such difference was observed in HFD-fed mice. In addition, plasma free fatty 
acids (FFAs) concentrations did not differ significantly between both groups 20 weeks after 
surgery. Similarly, bile acids levels were not different between sham-operated and UniNx 
mice. Additionally, uric acid levels were comparable between HFD-fed sham-operated and 
UniNx mice. 
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Figure 7  Metabolic cage analyses. Respiratory quotient (RQ) (A), locomotor activity (B) and food intake 
(C) was determined in HFD-fed sham-operated (black symbols) and UniNx (grey symbols) mice. n=7-8. 
Error bars represent SEM. 
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 Sham-operated UniNx 
 Chow HFD Chow HFD 
Glucose (mmol/l) 
n 
7.8 ± 0.7 
7 
11.7 ± 0.8## 
10 
8.8 ± 0.4 
8 
11.9 ± 0.8## 
10 
Insulin (ng/ml) 
n 
1.6 ± 0.2 
7 
7.0 ± 0.6### 
10 
0.9 ± 0.1** 
8 
5.9 ± 0.8### 
10 
FFA (mmol/l) 
n 
n.d. 
 
0.72 ± 0.9 
5 
n.d. 
 
0.79 ± 0.9 
5 
Uric acid (mg/dl) 
n 
n.d. 
 
4.4 ± 0.4 
8 
n.d. 
 
5.4 ± 0.8 
9 
Bile acids (µmol/l) 
n 
8.4 ± 3.1 
7 
9.4 ± 1.3 
10 
8.2 ± 2.3 
8 
14.0 ± 4.0 
10 
 
 
3.1.5 Increased circulating creatinine and cystatin C levels in HFD-fed 
UniNx mice 
            Twenty weeks after surgery, serum creatinine levels in HFD-fed UniNx mice were 
slightly, but significantly increased (Figure 8A). Nonetheless, the increased creatinine 
concentration in UniNx mice was still within normal limits. Of note, normal creatinine 
levels in mice range from 0.164 to 0.942 mg/dl. Cystatin C levels, which is a more accurate 
readout for glomerular infiltration rate (GFR) than serum creatinine, were significantly 
higher in HFD-fed UniNx mice (Figure 8B) suggesting decreased GFR in HFD-fed UniNx 
compared to sham-operated mice.  
Table 2  Circulating blood parameters in sham-operated and UniNx mice. Results are means and SEM 
of 7 to 17 animals per group. *p<0.05, **p<0.01, ***p<0.001 compared to sham-operated mice; #p<0.05, 
##p<0.01, ###p<0.001 compared to chow-fed mice; n.d. - not determined 
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3.2    Similar overall insulin sensitivity and glucose tolerance in HFD-fed      
UniNx and sham-operated mice 
            Intraperitoneal glucose and insulin tolerance tests were performed 2, 8 and 20 
weeks after surgical intervention in chow- and HFD-fed sham-operated and UniNx mice. In 
chow-fed animals, glucose and insulin tolerance tests were similar at all time points 
evaluated (Figure 9). Interestingly though, there was an unexpected trend towards 
improved glucose tolerance in chow-fed UniNx compared to sham-operated mice 20 weeks 
after surgery (Figure 9Aiii). HFD-fed mice showed the expected deterioration in glucose 
and insulin tolerance. However, glucose and insulin tolerance tests were not different 
between HFD-fed sham-operated and UniNx mice except for slightly higher glucose levels 
in UniNx mice after 8 weeks of HFD (Figure 9Aii).  
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Figure 8  Increased creatinine and cystatin C levels in HFD-fed UniNx mice. Serum creatinine (A) and 
plasma cystatin C (B) were determined 20 weeks after surgery in HFD-fed sham-operated (black bars) and 
UniNx mice (grey bars) mice. n=6-9. *p < 0.05, **p < 0.01 (Student’s t test). Error bars represent SEM. 
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            In order to more accurately determine insulin sensitivity, hyperinsulinaemic-
euglycaemic clamp studies were performed in HFD-fed mice 20 weeks after surgery. As 
depicted in Figure 10B and 10C, overall (total body) insulin sensitivity was similar 
between HFD-fed sham-operated and UniNx mice. 
 
0 30 60 90 120
0
5
10
15
20
25
30
35
B
lo
o
d
 g
lu
c
o
se
 (
m
M
)
Time (min)
0 30 60 90 120
0
5
10
15
20
25
30
35
B
lo
o
d
 g
lu
c
o
se
 (
m
M
)
*
Time (min)
0 30 60 90 120
0
5
10
15
20
25
30
35
B
lo
o
d
 g
lu
c
o
se
 (
m
M
)
Time (min)
0 30 60 90 120
0
2
4
6
8
10
12
14
B
lo
o
d
 g
lu
c
o
se
 (
m
M
)
Time (min)
0 30 60 90 120
0
2
4
6
8
10
12
14
B
lo
o
d
 g
lu
c
o
se
 (
m
M
)
Time (min)
0 30 60 90 120
0
2
4
6
8
10
12
14
B
lo
o
d
 g
lu
c
o
se
 (
m
M
)
Time (min)
A B 
i i 
 
ii ii 
iii iii 
Figure 9  Similar overall insulin sensitivity and glucose tolerance in UniNx mice compared to sham-
operated mice. Intraperitoneal glucose tolerance test (A) and insulin tolerance test (B) were performed at (i) 
2, (ii) 8, (iii) 20 weeks after surgery. Results are means and SEM of 7 to 17 animals per group. *p < 0.05, **p 
< 0.01 (Student’s t test).      Sham chow;     UniNx chow;     sham HFD;     UniNx HFD. 
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3.3    Improved hepatic but deteriorated muscle insulin sensitivity in   
HFD-fed UniNx mice 
            Endogenous glucose production (EGP), mainly reflecting hepatic glucose 
production, was determined during hyperinsulinaemic-euglycaemic clamp. As depicted in 
Figure 11A, insulin-induced suppression of EGP was blunted in HFD-fed sham-operated 
mice, but clearly evident in HFD-fed UniNx mice indicating improved/preserved hepatic 
insulin sensitivity in HFD-fed UniNx mice. In contrast, insulin-stimulated glucose disposal 
rate (IS GDR), mainly reflecting insulin-stimulated glucose disposal, was significantly 
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Figure 10  Blood glucose concentrations and glucose infusion rates during hyperinsulinaemic-
euglycaemic clamp. (A) Blood glucose levels were clamped upon insulin infusion at about 5 mmol/l in 
HFD-fed sham (black symbols) and UniNx (grey symbols) mice. (B) In order to maintain euglycaemia, 
glucose infusion rate was adjusted over time. (C) Glucose infusion rate (GIR) during hyperinsulinaemic-
euglycaemic clamps. Results are the mean + SEM of 5 animals per group.  
 
 
Results are means and SEM of 7 to 17 animals per group.    Sham chow;   UniNx chow;   sham HFD;   
UniNx HFD. 
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reduced by more than 50% in HFD-fed UniNx mice, suggesting that UniNx further 
deteriorated HFD-induced skeletal muscle insulin resistance (Figure 11B). 
 
 
 
 
 
 
 
 
 
 
3.4    Improved hepatic steatosis in HFD-fed UniNx mice 
            Consistent with improved hepatic insulin sensitivity (Figure 11A), total liver lipid 
content was greatly reduced in HFD-fed UniNx compared to sham-operated mice (Figure 
12A). Such result was supported by histological examination of liver sections revealing 
higher numbers of lipid vacuoles in HFD-fed sham-operated mice (Figure 12B). 
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Figure 11  Improved hepatic but deteriorated muscle insulin sensitivity in HFD-fed UniNx mice. 
Hyperinsulinaemic-euglycaemic clamp studies were performed in HFD-fed sham-operated (black bars) and 
uninephrectomised (grey bars) mice 20 weeks after surgery. Insulin-mediated inhibition of endogenous 
glucose production (EGP) corresponding to hepatic insulin sensitivity is depicted in (A). Insulin-stimulated 
glucose disposal rate (IS GDR) reflecting muscle insulin sensitivity is shown in (B). Results are the mean + 
SEM of 5 animals per group. *p < 0.05, **P < 0.01 (Student’s t test). 
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3.5    Reduced adipose tissue inflammation in HFD-fed UniNx mice 
            The ‘portal theory’ proposes that the direct exposure of the liver to increasing 
amounts of FFAs and/or pro-inflammatory factors released from visceral fat into the portal 
vein may promote the development of hepatic insulin resistance and steatosis [23]. 
Accordingly, mRNA expression of pro-inflammatory cytokines as well as adipose tissue 
histology was analysed in order to characterize adipose tissue inflammation. As depicted in 
Figure 13A, expression of CD11c (a marker for pro-inflammatory M1 polarized 
macrophages) and IL-6 was significantly decreased and expression of TNF and IL-1 
trendwise reduced in mesenteric adipose tissue of HFD-fed UniNx compared to sham-
operated mice. Of note, mRNA levels of the hypoxia-inducible factor 1-alpha (HIF1) was 
significantly lower in mesenteric adipose tissue of HFD-fed UniNx mice. Histologically, 
obesity is associated with macrophage infiltration in adipose tissue and these macrophages 
seem to form so called crown-like structures by surrounding mainly necrotic, hypertrophic 
adipocytes. In obese sham-operated mice, macrophages and crown-like structures were 
easily detected in HFD-fed sham-operated mice, whereas, they were less prominent in 
HFD-fed UniNx mice (Figure 13B). In contrast, adipocyte diameter was not different 
  Sham                                                                           UniNx 
B 
50 m 50 m 
Figure 12  Improved hepatic steatosis in HFD-fed UniNx mice. (A) Total liver lipids were determined 
and expressed relative to total liver in HFD-fed sham-operated (black bar) and uninephrectomised (grey 
bar) mice 20 weeks after surgery. (B) Representative hematoxylin-eosin stained histological sections of 
liver of HFD-fed sham-operated and UniNx mice. Scale bar represent 50 m. Results are the mean + SEM 
of 5-7 animals per group. *p < 0.05 (Student’s t test). 
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between both groups of mice (Figure 13C). Moreover, insulin-stimulated Akt-
phosphorylation in adipose tissue was similar in both groups suggesting similar insulin 
sensitivity in these tissues (Figure 13D). Thus, in addition to improved/preserved hepatic 
insulin sensitivity, uninephrectomy protects mice from the development of HFD-induced 
adipose tissue inflammation. 
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3.6    Similar skeletal muscle insulin action ex vivo 
            Glucose uptake into isolated soleus (slow-twitch) and extensor digitorum longus 
(fast-twitch) muscles was assessed next removing extramyocellular barriers to muscle 
glucose uptake. As depicted in Figure 14A and 14B, basal and insulin-stimulated glucose 
uptake were similar between HFD-fed sham and UniNx mice, suggesting no direct 
impairment of insulin action at the myocyte level. Of note, 20 weeks of HFD led to an 
expected poor insulin response in skeletal muscle, which was particularly evident in soleus 
muscle. Similarly, no difference between both groups of mice was found for ex vivo 
insulin-stimulated Akt phosphorylation (Figure 14C) in total muscle homogenates. These 
data in isolated muscle contrast the data obtained from hyperinsulinaemic-euglycaemic 
clamp studies revealing diminished muscle insulin sensitivity in HFD-fed UniNx mice 
(Figure 11B) and may indicate that UniNx leads to impaired insulin delivery to the 
sarcolemma, e.g. through reduction in capillary density. 
 
 
 
 
 
 
 
Figure 13  Reduced adipose tissue inflammation in HFD-fed UniNx mice. (A) mRNA expression of 
respective genes in mesenteric adipose tissue of HFD-fed sham-operated (black bars) and uninephrectomised 
(grey bars) mice 20 weeks after surgery, n=5-10. *p < 0.05 (Student’s t test). (B) Representative hematoxylin-
eosin stained histological sections of epididymal adipose tissue of HFD-fed sham-operate and UniNx mice. 
(C) Adipocyte cell perimeter was measured by using Image J. Up to 100 cells per fat pad of four different 
mice per group was analysed. All values are expressed relative to the adipocyte cell perimeter of HFD-fed 
sham-operated mice. Scale bar represent 100 m. (D) Lysates of white adipose tissue were prepared, resolved 
by LDS-PAGE and immunoblotted with anti-pS473AKT, anti-total Akt or anti-actin antibody. Graphs from B 
to D show results of 4-5 mice. Results are the mean + SEM. (ATGL: adipose triglyceride lipase) 
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3.7    Reduced capillary density in skeletal muscle of HFD-fed UniNx 
mice 
            In order to assess capillary density, expression of the endothelial marker CD31 was 
determined. As depicted in Figure 15A, mRNA levels of CD31 were significantly reduced 
in quadriceps muscle in HFD-fed UniNx compared to sham-operated mice. Moreover, 
capillary-to-fiber ratio was significantly (~15%) reduced in skeletal muscle of HFD-fed 
UniNx mice (Figure 15B and C). These results suggest that uninephrectomy leads to a 
reduction in muscle capillary density in HFD-fed mice. 
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Figure 14  Preserved/sustained insulin-stimulated glucose uptake into skeletal muscle ex vivo in HFD-
fed UniNx mice. Glucose uptake into intact isolated soleus muscle (A) and extensor digitorum longus (EDL) 
(B) was measured in the absence or presence of 120 nM insulin.  n=8. Basal state (open bars), insulin-
stimulated state (black bars). (C) Total muscle lysates were prepared, resolved by LDS-PAGE and 
immunoblotted with anti-pS473 Akt, anti-total Akt or anti-actin antibody. Graphs show results of 4-5 mice. 
Error bars represent SEM. 
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Figure 15  Reduced capillary density in skeletal muscle of HFD-fed UniNx mice. (A) mRNA expression 
of CD31 and HIF in quadriceps muscle of HFD-fed sham-operated (black bars) and UniNx mice (grey 
bars). n=4-5. (B and C) CD31 staining of quadriceps muscle isolated from HFD-fed sham-operated and 
UniNx mice. Capillary-to-fiber ratio was calculated after counting up to 700 fibers and corresponding 
capillaries per mouse. n=4. Error bars represent SEM. *p < 0.05 (Student’s t test). 
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3.8    Increased plasma angiotensin I levels in UniNx mice 
             As outlined in the introduction, activation of the renin-angiotensin-system (RAS) 
may contribute to HFD/obesity-induced insulin resistance. In addition, UniNx-induced 
reduction in kidney mass may result in increased angiotensin levels; and thus may 
contribute to observed deterioration of skeletal muscle insulin resistance [154-156]. Indeed, 
plasma angiotensin I level was elevated in UniNx compared to sham-operated mice under 
both chow and HFD 2, 8 and 20 weeks after surgical intervention (Figure 16) (data not 
shown for time points 2 and 8 weeks). 
 
 
 
 
 
 
 
3.9    Improved glucose tolerance in telmisartan-treated HFD-fed sham-
operated mice 
            Since it was postulated that inappropriate activation of the renin-angiotensin system 
(RAS) induces HFD-associated skeletal muscle insulin resistance, we hypothesized that the 
observed increase in circulating angiotensin I concentration deteriorates HFD-induced 
skeletal muscle insulin resistance via activation of angiotensin II type 1 receptor (AT1R). 
To test such hypothesis we made use of the AT1R blocker telmisartan. UniNx and sham-
operated mice were fed a HFD for 20 weeks and received telmisartan in the drinking water 
at a dose of 3mg/kg*day during the entire period. As depicted in Figure 17A, telmisartan-
treated HFD-fed sham-operated mice gained much less body weight than untreated controls 
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Figure 16  Increased angiotensin I levels in UniNx mice. Plasma angiotensin I levels were determined in 
sham-operated (black bars) and UniNx mice (grey bars) 20 weeks after surgery. Results are the mean + 
SEM of 8 animals per group. *p < 0.05 (Student’s t test). 
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and telmisartan-treated HFD-fed UniNx mice. Nevertheless, body weight gain in the latter 
mice was reduced compared to untreated UniNx controls (Figure 17A). Moreover, 
telmisartan treatment improved glucose tolerance in HFD-fed sham-operated but not 
UniNx mice (Figure 17B and C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.10    Improved hepatic insulin sensitivity in telmisartan-treated HFD- 
fed sham-operated mice 
            In addition to glucose tolerance test, we next determined insulin sensitivity in 
telmisartan-treated HFD-fed mice by means of hyperinsulinaemic-euglycaemic clamp 
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Figure 17  Telmisartan improves glucose tolerance in HFD-fed sham-operated mice. (A) Body weights 
of uninephrectomised (UniNx) and sham-operated mice. n=5.     Sham HFD;    UniNx HFD;    Telmisartan-
treated sham HFD;  Telmisartan-treated UniNx HFD. (B) Intraperitoneal glucose tolerance test in 
telmisartan-treated HFD-fed sham-operated and UniNx mice. n=11. (C) Analysis of area under the curve of 
glucose tolerance tests presented in B. All error bars represent SEM. 
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study. As depicted in Figure 18A, glucose infusion rate was elevated in telmisartan-treated 
HFD-fed sham-operated mice indicating that telmisartan ameliorated total body insulin 
sensitivity in HFD-fed sham-operated mice. In contrast, glucose infusion rate (GIR) in 
telmisartan-treated HFD-fed UniNx was comparable to the rate observed in untreated 
HFD-fed UniNx controls (GIR in telmisartan-treated HFD-fed UniNx mice (Figure 18A): 
45.1 ± 3.5 mg/kg*min; GIR in untreated HFD-fed UniNx mice (Figure 10C): 35.1 ± 3.9 
mg/kg*min; p=0.10). Particularly, telmisartan improved insulin-induced suppression of 
hepatic glucose production in HFD-fed sham-operated mice, whereas rate of insulin-
induced EGP-suppression was similar in telmisartan-treated and untreated HFD-fed 
UniNx mice (Figure 18B and Figure 11A). 
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Figure 18  Telmisartan improves hepatic insulin sensitivity in HFD-fed sham-operated mice. (A) 
Glucose infusion rate (GIR) and (B) insulin-mediated inhibition of endogenous glucose production 
corresponding to hepatic insulin sensitivity. (C) Blood glucose levels were clamped upon insulin infusion at 
about 5 mmol/l in telmisartan-treated HFD-fed sham (black circles) and UniNx (grey circles) mice. (D) In 
order to maintain euglycaemia, glucose infusion rate was adjusted over time. n=5. All error bars represent 
SEM. 
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3.11    Improved hepatic steatosis in telmisartan-treated HFD-fed sham- 
operated mice 
            In accordance with elevated hepatic insulin sensitivity, telmisartan treatment 
reduced hepatic steatosis in sham-operated mice (total liver lipids in untreated HFD-fed 
sham-operated mice: 299.4 ± 59.6 mg/g liver tissue; total liver lipids in telmisartan-treated 
HFD-fed sham-operated mice: 158.0 ± 31.8 mg/g liver tissue) but did not affect liver lipids 
in UniNx mice (total liver lipids in untreated HFD-fed UniNx mice: 123.4 ± 17.7 mg/g 
liver tissue; total liver lipids in telmisartan-treated HFD-fed UniNx mice: 178.5 ± 22.8 
mg/g liver tissue) resulting in similar total liver lipids in telmisartan-treated mice of both 
groups (Figure 19).  
 
 
 
 
 
 
 
 
3.12    Similar pro-inflammatory cytokines expression levels in   
telmisartan-treated HFD-fed sham-operated and UniNx mice 
            In parallel to improved/decreased hepatic steatosis, mRNA expression levels of pro-
inflammatory cytokines in mesenteric adipose tissue were similar between telmisartan-
treated HFD-fed sham-operated and UniNx mice. Of note, expression of HIF1 was no 
longer different between telmisartan-treated sham-operated and UniNx mice (Figure 20). 
These data suggest that telmisartan-treatment improved adipose tissue inflammation in 
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Figure 19  Telmisartan improves hepatic steatosis in HFD-fed sham-operated mice. Total liver lipids 
were determined and expressed relative to total liver weight in telmisartan-treated HFD-fed sham-operated 
(black bar) and UniNx mice (grey bar). n=5-6. All error bars represent SEM. 
 
Results 
39 
 
HFD-fed sham-operated mice since the observed difference in cytokine mRNA expression 
in untreated mice was no longer present.  
 
 
 
 
 
 
 
 
3.13    No effect of telmisartan-treatment on muscle insulin resistance and  
capillary rarefaction in HFD-fed UniNx mice 
            Previously, the angiotensin II receptor blocker losartan was found to reverse insulin 
resistance through the modulation of muscular circulation in rats with impaired glucose 
metabolism [157]. We therefore postulated that telmisartan improves muscle insulin 
sensitivity as well as capillary density in UniNx mice. However, as depicted in Figure 21A, 
20 weeks of telmisartan-treatment did not improve insulin-stimulated glucose disposal rate 
(IS-GDR) in UniNx mice (IS-GDR in untreated HFD-fed UniNx mice (Figure 11B): 10.6 
± 1.2 mg/kg*min; IS-GDR in telmisartan-treated HFD-fed UniNx mice (Figure 21A): 4.2 
± 2.3 mg/kg*min). Accordingly, insulin stimulated glucose uptake was significantly higher 
in telmisartan-treated HFD-fed sham-operated compared to UniNx mice (Figure 21B). 
Moreover, CD31 expression remained reduced in quadriceps muscle of telmisartan-treated 
HFD-fed UniNx compared to sham-operated mice (Figure 21C). Thus, telmisartan- 
treatment positively impacts on total body and hepatic insulin sensitivity in HFD-fed sham- 
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Figure 20  Similar expression of pro-inflammatory cytokines in telmisartan-treated sham-operated 
and UniNx mice. mRNA expression of respective genes in mesenteric adipose tissue of telmisartan-treated 
HFD-fed sham-operated (black bars) and UniNx mice (grey bars). n=4-5. Error bars represent SEM. *p < 
0.05 and **p < 0.01 (Student’s t test). 
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operated mice but does not affect impaired skeletal muscle insulin sensitivity in HFD-fed 
UniNx mice. 
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Figure 21  No effect of telmisartan-treatment on muscle insulin resistance and capillary rarefaction in 
HFD-fed UniNx mice. (A) Insulin-stimulated glucose disposal rate (IS GDR) and (B) insulin-stimulated 
glucose uptake into quadriceps muscle during hyperinsulinaemic-euglycaemic clamps (n=4). (C) mRNA 
expression of CD31 and HIF1a in quadriceps muscle of HFD-fed sham-operated (black bars) and UniNx 
mice (grey bars). n=4-5. Error bars represent SEM. *p < 0.05 and **p < 0.01 (Student’s t test). 
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4      Discussion 
 
            To date, there is increasing evidence that obese patients are more susceptible to the 
development of progressive renal damage as a consequence of their obesity-related 
comorbidities, such as T2DM [107]. Conversely, even mild renal dysfunction is thought to 
increase the risk for developing multiple metabolic derangements, including insulin 
resistance, an important concern in overweight patients who are already prone to 
developing T2DM [118, 158]. Although the association between obesity and T2DM are 
considered established, little is known about their relation to the long-term outcomes in 
living kidney donor.  Several studies have shown that long term consequences of live 
kidney donation may include a higher propensity of metabolic syndrome, including 
dyslipidaemia and insulin resistance [100]. Yet, increasing demand for live-donor kidneys 
has encouraged the use of obese donors despite the evidences that obesity can adversely 
affect renal function [7]. In view of those observations, we hypothesize that reduced kidney 
mass which can be induced experimentally in animals by uninephrectomy, may lead to the 
appearance of all the type 2 diabetes-related traits, as if were, when the animals are 
challenged in parallel with a HFD. In order to determine whether obese mice were more 
sensitive to experimental reduced kidney mass, the relation between obesity and 
uninephrectomy was studied in C57BL/6 mice on long-term outcomes. This was achieved 
by subjecting lean and obese mice to two experimental protocols: (1) feeding mice on chow 
or high fat diet after surgical uninephrectomy for up to 20 weeks (2) the treatment of obese 
mice with the angiotensin II receptor blocker i.e. telmisartan. The specific aim of the 
project was to test possible mechanism of the RAS activation through which reduced 
kidney mass may lead to related metabolic disorders by altering the adipose tissue 
distribution and whole-body glucose homeostasis in diet-induced obese mice.  
            A potential methodological problem to consider when using contralateral remnant 
kidney mouse model is whether this model could resemble progressive renal disease, and 
thus, mimic some clinical aspects of kidney donation in human. It was reported that 
uninephrectomy leads to progressive kidney dysfunction in rats over a period of time, but it 
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is not enough to cause CKD progression in C56BL/6 mice [119, 123]. Kidney contributes 
to whole body metabolism, e.g. to endogenous glucose production [105]. Therefore, a 
reduction of the functional kidney mass (i.e., a decrease in the number of nephrons), may 
impact on total body metabolism and homeostasis. On the other hand, as discussed above, 
diet-induced obesity may also propagate the development of progressive renal disease 
[110]. 
            Based on the published data of gene expression analysis in mouse kidney samples 
(same animal samples in our group) by whole genome microarrays in the laboratory of Prof. 
Gerd Kullak, the impact of HFD on gene expression was stronger than the impact of 
uninephrectomy. The net effect of uninephrectomy in chow-fed mice was minimal. The 
studies revealed that the impact of surgical intervention on gene expression between the 
UniNx-chow/sham-chow groups and the UniNx-HFD/sham-HFD groups were 157 and 136 
genes, respectively. In contrast, the impact of HFD was much more significant: 2441 and 
2581 gene changes were observed in the groups of sham-HFD versus sham-chow and the 
groups of UniNx-HFD versus UniNx-chow, respectively. Of note, the combination of 
UniNx and HFD additionally altered the effects of obesity on gene expression pattern. 
These data have given us a hint that diet-induced obesity induces metabolic stress and gene 
expression changes, and these changes were further enhanced by reduced kidney mass.  
[159, 160].  
            As shown in Figure 6A, the remnant kidneys of UniNx were heavier than sham-
operated mice. Nonetheless, removal of 50% of the renal mass was associated with 
increased cystatin C and creatinine levels in UniNx HFD-fed mice indicating decrease in 
renal function in these mice (Figure 8B). Of note, changes in creatinine levels in HFD-fed 
UniNx mice were within normal limits (Figure 8A). More recently, determination of 
cystatin C has been proposed to provide a more accurate estimation of the GFR and to be 
more sensitive in the identification of reduced kidney function than measurement of serum 
creatinine concentration [161]. Furthermore, it may be a biomarker for potential organ 
dysfunction in patients with the metabolic syndrome, as it may reflect a response to adipose 
tissue remodelling and ectopic fat deposition [162]. Thus, the markedly increased cystatin 
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C levels in HFD-fed UniNx mice may indicate that uninephrectomy has further aggravated 
HFD-induced metabolic dysfunction.  
            In order to test the impact of HFD and/or reduced kidney mass on glucose 
homeostasis, glucose and insulin tolerance was assessed 2, 8, 20 weeks after surgical 
intervention. As expected, impaired glucose tolerance and insulin resistance developed in 
HFD-fed mice compared to standard chow-fed mice (Figure 9). However, both ipGTT 
and ipITT were similar in UniNx and sham-operated mice under both standard chow as 
well as HFD. Using hyperinsulinaemic-euglycaemic clamp, which is considered the gold-
standard method to assess insulin sensitivity in vivo, total body insulin sensitivity was 
similar between HFD-fed UniNx and sham-operated mice (Figure 10). The beauty of the 
clamp studies is that insulin sensitivity can be determined in different insulin-sensitive 
organs. However and surprisingly, uninephrectomised mice were protected from HFD-
induced hepatic insulin resistance, but showed deteriorated skeletal muscle resistance 
(Figure 11). This unusual finding of discrepant hepatic and muscle insulin sensitivity 
begged for the question: what are the potential mechanisms for such discrepancy? 
            Obesity-associated hepatic insulin sensitivity may be at least partly mediated by 
adipose tissue inflammation. Particularly, the “portal theory” is claiming that exaggerated 
release of pro-inflammatory cytokines and/or FFAs from visceral fat directly delivered to 
the liver via portal vein promotes the development of hepatic insulin resistance (and 
hepatic steatosis) [23, 163]. Further supporting such notion we found herein reduced 
visceral adipose tissue inflammation in HFD-fed UniNx mice associated with improved 
hepatic insulin sensitivity and steatosis (Figure 12 and Figure 13A). Of note, expression 
of HIF1α was reduced in adipose tissue of HFD-fed UniNx mice (Figure 13A). Selective 
inhibition of HIF1α was previously reported to reduce adipose tissue inflammation as well 
as hepatic steatosis in HFD-fed mice [19]. Conversely, overexpression of HIF1induced 
adipose tissue fibrosis and inflammation as well as hepatic steatosis [20]. Thus, 
uninephrectomy is associated with decreased HIF1a expression in adipose tissue and 
thereby may contribute to reduced adipose inflammation; and consequently preserved 
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hepatic insulin sensitivity. Such notion is further supported by the fact that treatment with 
telmisartan abolished differences in mRNA expression of HIF1α as well as pro-
inflammatory cytokines and improved hepatic insulin sensitivity in sham-operated mice 
(Figure 20). Currently, it remains to be elucidated how uninephrectomy regulates/ 
modulates HIF1α expression in adipose tissue.  
            However, improved hepatic insulin sensitivity may be independent of adipose 
tissue inflammation. Intriguingly, unpublished findings in the laboratory of Prof. Gerd 
Kullak have recently described a two fold increase in bile acid levels in UniNx mice. Bile 
acids were recently reported to activate the farnesoid X receptor (FXR) and thereby 
reversing HFD-induced hepatic insulin resistance and improving hepatic steatosis [164]. 
Moreover, recent clinical studies have suggested that FXR activation appears to improve 
insulin resistance and fatty liver status in patients with T2DM [165]. Herein, we found a 
trend towards increased bile acid levels in HFD-fed UniNx compared to sham-operated 
mice, although such difference did not reach statistical significance (Table 1). Thus, 
increased circulating bile acid levels may have at least partly contributed to improved 
hepatic insulin sensitivity and steatosis in HFD-fed UniNx mice. 
            In contrast to improved hepatic insulin sensitivity, skeletal muscle insulin 
sensitivity was further deteriorated in HFD-fed UniNx mice. The precise mechanism how 
UniNx may negatively impact on skeletal muscle insulin sensitivity remains unclear. The 
observed discrepancy of preserved muscle insulin sensitivity ex vivo but deteriorated 
muscle insulin resistance in vivo indicated impaired insulin delivery to the sarcolemma in 
UniNx mice. It was previously reported that insulin increases microvascular blood flow to 
the muscle contributing to approximately half of the insulin-mediated glucose uptake [78]. 
Accordingly, muscle capillary density strongly correlates with peripheral insulin action 
[166]. Conversely, capillary rarefaction was associated with insulin resistance both in 
humans and rodents [79, 83, 84]. Thus, UniNx may propagate capillary rarefaction of 
skeletal muscle. Indeed, mRNA expression and histological staining of CD31 were 
decreased pointing towards reduced capillary density in skeletal muscle of HFD-fed 
UniNx mice (Figure 15). Our results are in accordance with Flinsinski et al, who reported 
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reduced numbers of capillaries as well as a decreased capillary-to-fiber ratio in 
gastrocnemius and longissimus muscle in UniNx male Wistar rats [167]. Of note, 
treatment with the angiotensin II receptor blocker telmisartan had no impact on capillary 
density in UniNx mice suggesting that UniNx-associated capillary rarefaction is not 
dependent on activation of the RAS whereas it may modulate muscular circulation and 
thereby insulin sensitivity as was previously reported for the angiotensin II receptor 
blocker losartan in rats [84]. Potentially, reduced muscle capillary density may relate to 
decreased HIF1a mRNA expression in skeletal muscle of UniNx mice. HIF1 is the 
master regulator of transcriptional responses to hypoxia and a transcriptional activator of 
gene encoding vascular endothelial growth factor (VEGF) and other important mediators 
of angiogenesis [80]. Importantly, UniNx and subtotal nephrectomy in Wistar rats were 
associated with reduced expression of HIF1, VEGF A and VEGF receptor in 
gastrocnemius muscle [168]. Moreover, muscle-specific deletion of VEGF resulted in 
capillary rarefaction and diminished insulin-induced muscle glucose uptake in vivo 
independent of defects in insulin action at the myocyte [83]. Thus, reduced expression of 
HIF1 may be causally linked to reduced capillary density observed in skeletal muscle of 
UniNx mice. 
            There is evidence activation of the RAS/angiotensin receptors (ATRs) impairs 
insulin signalling in adipose tissue, skeletal muscle, and liver by inducing oxidative stress 
and/or activating serine kinases such as NFB and ERK1/2 leading to impaired insulin 
signalling [169]. Overnutrition may activate the RAS, and thus may contribute to the 
pathogenesis of insulin resistance, particularly in the presence of reduced renal function 
[39, 107]. Thus, we hypothesized that the observed deterioration of muscle insulin 
sensitivity in UniNx mice was due, at least partly, to activation of the RAS. Indeed, we 
found indirect evidence for activation of the RAS in UniNx mice as demonstrated by 
increased angiotensin I levels 2, 8, 20 weeks after surgery (Figure 16). 
            However, treatment with the angiotensin II type I receptor blocker telmisartan did 
not improve skeletal muscle insulin sensitivity and had no impact on capillary density in 
UniNx mice, suggesting that UniNx-associated capillary rarefaction is not dependent on 
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activation of the RAS whereas it may modulate muscular circulation and thereby insulin 
sensitivity, as was previously reported for the angiotensin II receptor blocker losartan in 
rats [84]. In contrast, telmisartan-treatment improved glucose tolerance in HFD-fed sham-
operated mice, probably via reduction of adipose tissue inflammation, and consequently 
preservation of hepatic insulin sensitivity [40, 170]. Accordingly, treatment with 
telmisartan abolished differences in mRNA expression of HIF1 as well as pro-
inflammatory cytokines between UniNx and sham-operated mice and improved hepatic 
insulin sensitivity in the latter. Of note, lacking effect of telmisartan-treatment on insulin 
resistance and increased circulating angiotensin I levels in HFD-fed UniNx mice may be 
explained by the development of angiotensin II resistance in these mice.  
            In conclusion, UniNx unexpectedly protects HFD-fed mice from obesity-induced 
adipose tissue inflammation and hepatic insulin resistance potentially via a reduction in 
HIF1 expression. In contrast, UniNx leads to capillary rarefaction in skeletal muscle and, 
thus, deteriorates HFD-induced skeletal muscle glucose disposal in vivo. 
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